Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1.
Spans L, Van den Broeck T, Smeets E, Prekovic S, Thienpont B, Lambrechts D, Karnes RJ, Erho N, Alshalalfa M, Davicioni E, Helsen C, Gevaert T, Tosco L, Haustermans K, Lerut E, Joniau S, Claessens F.
Spans L, et al.
Oncotarget. 2016 Apr 26;7(17):24326-38. doi: 10.18632/oncotarget.8220.
Oncotarget. 2016.
PMID: 27014907
Free PMC article.